References
- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(10)2276–2277
- Stasi R, Stipa E, Masi M, Cecconi M, Scimò MT, Oliva F, Sciarra A, Perrotti AP, Adomo G, Amadori S, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98(5)436–442
- Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13)995–1008
- Domenico Sebastiani G, Minisola G, Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev 2003; 2(6)387–394
- Vargas-Alarcon G, Granados J, Bekker C, Alcocer-Varela J, Alarcón-Segovia D. Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. Arthritis Rheum 1995; 38: 1340–1343
- Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008; 22(4)187–194
- Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an International working Group. Blood 2009; 113: 2386–2393
- Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190–4207
- Nomura S, Matsuzaki T, Ozaki Y, Yamaoka M, Yoshimura C, Katsura K, Xie GL, Kagawa H, Ishida T, Fukuhara S. Clinical significance of HLA-DRB1*0410 in Japanese Patients with idiopathic thrombocytopenic purpura. Blood 1998; 91: 3616–3622
- Nomura S, Ishii K, Inami N, Matsuzaki T, Yamaoka M, Urase F, Maeda Y, Fukuhara S. Antiglycoprotein IIb-IIIa autoantibody in a patient with immune thrombocytopenia after cord blood transplantation. Clin Appl Thromb Hemost 2009; 15: 123–124
- Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol 2006; 81(6)391–396
- Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, Turgut M, Keskin H, Nalçaci M, Inanç M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study. Blood. 2001; 98(6)1760–1764
- Cuadrado MJ, Mujic F, Munoz E, Khamashta MA, Hughes GR. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997; 56(3)194–196
- Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Noncriteria APS Manifestations (II): Thrombocytopenia and skin manifestations. Lupus 2011; 20: 174–181
- Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: A case report and review of literature. Lupus. 2008; 17(1)50–55